Tyra Biosciences (TYRA) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Tyra Biosciences (NASDAQ: TYRA) in the last few weeks:

• 2/3/2026 – Tyra Biosciences had its price target raised by analysts at Jefferies Financial Group Inc. from $32.00 to $43.00. They now have a “buy” rating on the stock.
• 1/27/2026 – Tyra Biosciences is now covered by analysts at Barclays PLC. They set an “overweight” rating on the stock.
• 1/24/2026 – Tyra Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/23/2026 – Tyra Biosciences had its price target raised by analysts at Piper Sandler from $33.00 to $42.00. They now have an “overweight” rating on the stock.
• 1/21/2026 – Tyra Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/4/2026 – Tyra Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/27/2025 – Tyra Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/16/2025 – Tyra Biosciences had its price target raised by analysts at Wedbush from $30.00 to $37.00. They now have an “outperform” rating on the stock.

Insider Activity

In related news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.20% of the company’s stock.

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.